Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men

Abstract

Recently, soluble CD36 (sCD36) levels were reported to be elevated in type 2 diabetes, and to be tightly correlated with insulin resistance. Our aim was to obtain further insight into the relationship between insulin sensitivity, low-grade inflammation and sCD36.

We studied glucose-tolerant (n=90) and glucose-intolerant (n=57) moderately obese men. Insulin sensitivity was measured by the frequent sample intravenous glucose tolerance test, and sCD36 by an in-house ELISA assay.

In glucose-intolerant subjects, sCD36 was negatively associated with insulin sensitivity and positively with interleukin-6 (IL-6), fasting glucose, fasting triglycerides, fat-free mass and platelet count. On multiple linear regression analyses, insulin sensitivity contributed 22% of sCD36 variance, independent of age, body mass index (BMI) and IL-6, in glucose-intolerant subjects. The level of sCD36 in subjects with glycosylated haemoglobin (HbA_1C) above the mean was higher than in those with HbA_1C values below the mean.

Insulin sensitivity is a predictor of sCD36 in men with impaired glucose tolerance. IL-6 is related to sCD36 but does not predict sCD36 independent of insulin sensitivity and BMI.

Keywords

diabetes glucose intolerance insulin resistance low grade inflammation obesity risk marker sCD36

References

1. Febbraio M , Hajjar DP , Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001;108:785–91.

2. Han J , Hajjar DP , Febbraio M , Nicholson AC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 1997;272:21654–9.

3. Silverstein RL , Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol 2000;11:483–91.

4. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–26.

5. Fernandez-Real JM , Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278–301.

6. Fernandez-Real JM , Broch M , Vendrell J , Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 2003;26:1362–8.

7. Black PH. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003;17:350–64.

8. Lehrke M , Lazar MA. Inflamed about obesity. Nat Med 2004;10:126–7.

9. Sjoholm A , Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006;22:4–10.

10.

10. Tuomisto TT , Riekkinen MS , Viita H , Levonen AL , Yla-Herttuala S. Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading – cDNA and protein array study. Atherosclerosis 2005;180:283–91.

11.

11. Sampson MJ , Davies IR , Braschi S , Ivory K , Hughes DA. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis 2003;167:129–34.

12.

12. Griffin E , Re A , Hamel N et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med 2001;7:840–6.

13.

13. Handberg A , Levin K , Hojlund K , Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 2006;114:1169–76.

14.

14. Fernandez-Real JM , Broch M , Richart C , Vendrell J , Lopez-Bermejo A , Ricart W. CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab 2003;88:1780–4.

15.

15. Shoelson SE , Lee J , Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793–801.

16.

16. Liang CP , Han S , Okamoto H et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004;113:764–73.

17.

17. Glintborg D , Hojlund K , Andersen M , Henriksen JE , Beck-Nielsen H , Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;31:328–34.

18.

18. Hollenbeck C , Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987;64:1169–73.

19.

19. Reaven GM , Hollenbeck CB , Chen Y-DI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989;32:52–5.

20.

20. Yki-Järvinen H , Koivisto VA. Effect of body composition on insulin sensitivity. Diabetes 1983;32:965–9.

21.

21. Orchard TJ , Becker DJ , Kuller LH , Wagener D , LaPorte RE , Drash AI. Age and sex variations in glucose tolerance and insulin responses: parallels with cardiovascular risk. J Chron Dis 1982;35:123–32.

22.

22. Yki-Järvinen H. Sex and insulin sensitivity. Metabolism 1984;33:1011–15.

23.

23. Hale PJ , Wright JV , Nattrass M. Differences in insulin sensitivity between normal men and women. Metabolism 1985;34:1133–8.

24.

24. Paula FJA , Pimenta WP , Saad MJA , Paccola GMGF , Piccinato CD , Foss MC. Sex-related differences in peripheral glucose metabolism in normal subjects. Diabetes Metab Rev 1990;15:234–9.

25.

25. Nuutila P , Knuuti J , Mäki M et al. Gender and insulin sensitivity in the heart and in skeletal muscles: studies using positron emission tomography. Diabetes 1995;44:31–6.

26.

26. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–74.

27.

27. Nicholson AC , Febbraio M , Han J , Silverstein RL , Hajjar DP CD36 in atherosclerosis. The role of a class B macrophage scavenger receptor. Ann N Y Acad Sci 2000;902:128–31.